Literature DB >> 31523145

Translation and Validation of the Turkish Version of Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).

Öznur Usta Yeşilbalkan1, Öznur Erbay1, Ayşe Nur Yüceyar2.   

Abstract

INTRODUCTION: Poor adherence is widely observed in MS as in other chronic diseases; therefore, improving adherence should be a significant treatment objective. Therefore, it is important to determine the causes of nonadherence and to make improvement plans by establishing a special measurement tool for MS patients. The aim of this study is to investigate validity and Turkish equivalence of The Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ) that developed by Paul Wicks and Michael Massagli in 2009.
METHODS: The sample of the methodological study comprised 198 MS patients who stayed in University Faculty of Medicine, Department of Neurology, MS clinic between July 2016 and February 2017. In the research, "Data Collection Form" and "MS-TAQ" was used. To conduct this study, permission was obtained from the university ethics committee and the hospital administration. All participants in the study were informed of the study's purpose and their role.
RESULTS: Translation procedure (forward and backward) and pre-test were performed for translation equivalence and linguistic adaptation. MS-TAQ's Cronbach alfa coefficient 0.83 were calculated. According to expert's suggestion modifications was made and content validity index was calculated with Davis technic between 1.0-1.4.
CONCLUSION: As a result, "MS-TAQ" has been found a sufficiently valid and reliable tool in Turkey.

Entities:  

Keywords:  Multiple sclerosis; adherence; validity

Year:  2018        PMID: 31523145      PMCID: PMC6732815          DOI: 10.29399/npa.23214

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  12 in total

1.  The content validity index: are you sure you know what's being reported? Critique and recommendations.

Authors:  Denise F Polit; Cheryl Tatano Beck
Journal:  Res Nurs Health       Date:  2006-10       Impact factor: 2.228

Review 2.  Medication adherence and persistence: a comprehensive review.

Authors:  Kem P Krueger; Bruce A Berger; Bill Felkey
Journal:  Adv Ther       Date:  2005 Jul-Aug       Impact factor: 3.845

3.  THE DUAL-FOCUS APPROACH TO CREATING BILINGUAL MEASURES.

Authors:  Sumru Erkut; Odette Alarcón; Cynthia García Coll; Linda R Tropp; Heidie A Vázquez García
Journal:  J Cross Cult Psychol       Date:  1999-03

4.  Emerging oral therapies in multiple sclerosis.

Authors:  Devon Conway; Jeffrey A Cohen
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

Review 5.  Multiple Sclerosis Epidemiology in Middle East and North Africa: A Systematic Review and Meta-Analysis.

Authors:  Pouria Heydarpour; Shayan Khoshkish; Shabnam Abtahi; Maziar Moradi-Lakeh; Mohammad Ali Sahraian
Journal:  Neuroepidemiology       Date:  2015-06-16       Impact factor: 3.282

6.  Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis.

Authors:  Ana Ožura; Lea Kovač; Saša Sega
Journal:  Clin Neurol Neurosurg       Date:  2013-12       Impact factor: 1.876

7.  Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Authors:  Francesco Patti
Journal:  Patient Prefer Adherence       Date:  2010-02-04       Impact factor: 2.711

8.  [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].

Authors:  D Misdrahi; P M Llorca; C Lançon; F J Bayle
Journal:  Encephale       Date:  2002 May-Jun       Impact factor: 1.291

9.  Adherence to long-term therapies: evidence for action.

Authors:  Sabina De Geest; Eduardo Sabaté
Journal:  Eur J Cardiovasc Nurs       Date:  2003-12       Impact factor: 3.908

10.  Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).

Authors:  Paul Wicks; Michael Massagli; Amit Kulkarni; Homa Dastani
Journal:  J Med Internet Res       Date:  2011-01-24       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.